Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle |
| |
Authors: | Yana Dekempeneer Marleen Keyaerts Ahmet Krasniqi Janik Puttemans Serge Muyldermans Tony Lahoutte |
| |
Affiliation: | 1. Vrije Universiteit Brussel, In Vivo Cellular and Molecular Imaging, Brussels, Belgiumyana.dekempeneer@vub.ac.be;3. Vrije Universiteit Brussel, In Vivo Cellular and Molecular Imaging, Brussels, Belgium;4. Nuclear Medicine Department, UZ Brussel, Brussels, Belgium;5. Vrije Universiteit Brussel, Laboratory of Cellular and Molecular Immunology, Brussels, Belgium |
| |
Abstract: | ABSTRACTIntroduction: The combination of a targeted biomolecule that specifically defines the target and a radionuclide that delivers a cytotoxic payload offers a specific way to destroy cancer cells. Targeted radionuclide therapy (TRNT) aims to deliver cytotoxic radiation to cancer cells and causes minimal toxicity to surrounding healthy tissues. Recent advances using α-particle radiation emphasizes their potential to generate radiation in a highly localized and toxic manner because of their high level of ionization and short range in tissue.Areas covered: We review the importance of targeted alpha therapy (TAT) and focus on nanobodies as potential beneficial vehicles. In recent years, nanobodies have been evaluated intensively as unique antigen-specific vehicles for molecular imaging and TRNT.Expert opinion: We expect that the efficient targeting capacity and fast clearance of nanobodies offer a high potential for TAT. More particularly, we argue that the nanobodies’ pharmacokinetic properties match perfectly with the interesting decay properties of the short-lived α-particle emitting radionuclides Astatine-211 and Bismuth-213 and offer an interesting treatment option particularly for micrometastatic cancer and residual disease. |
| |
Keywords: | Cancer targeting vehicles targeted alpha therapy radionuclide labeling nanobody bismuth-213 astatine-211 |
|
|